BioSpace

Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor

Sanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies contend with the looming loss of exclusivity of their blockbuster drug Dupixent.

作者 BioSpace

1 分钟阅读
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Health Tech相关内容

相关洞察